These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1156 related articles for article (PubMed ID: 17389244)

  • 1. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.
    Zapotocky M; Mejstrikova E; Smetana K; Stary J; Trka J; Starkova J
    Cancer Lett; 2012 Jun; 319(2):144-153. PubMed ID: 22261333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.
    Maiques-Diaz A; Chou FS; Wunderlich M; Gómez-López G; Jacinto FV; Rodriguez-Perales S; Larrayoz MJ; Calasanz MJ; Mulloy JC; Cigudosa JC; Alvarez S
    Leukemia; 2012 Jun; 26(6):1329-37. PubMed ID: 22289984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
    Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
    Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reversed effect of valproic acid on transcription inhibition of AML1-ETO fusion protein of kasumi-1 leukemic cell line].
    Zhao L; Zhu CM; Zhang ZH; Tian WL; Hao CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):363-7. PubMed ID: 19379567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
    Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
    Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
    Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
    Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line.
    Zhuang WY; Cen JN; Zhao Y; Chen ZX
    Oncol Rep; 2013 Jul; 30(1):185-92. PubMed ID: 23673926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
    Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
    J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
    Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
    Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism].
    Yu WJ; Wang L; You LS; Mei C; Ma QL; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):366-70. PubMed ID: 22781793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
    Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
    BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
    Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
    Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.
    Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ
    Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
    Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
    Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.